Trump to FDA: Boost Generics, OTCs, Rx Imports
Under a 4/15 presidential Executive Order, FDA has 180 days to issue a report with recommendations to (1) accelerate the approval of generics, biosimilars, combination products, and second-in-class branded medications; and (2) improve the process through which prescription drugs can be reclassified as over-the-counter medications.